Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eugene Wright

Internal Medicine Fayetteville, NC Medical Doctor

NPI 1528197555 CMS profile 341019

150 Robeson St, Suite 400, Fayetteville, NC 28301

Open in the dashboard

General payments

$838,901

1,039 records reported · program years 2019–2025

Research payments

$11,012

Paid to them · 16 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eugene Wright of Fayetteville, NC is reported in the CMS Open Payments database as having received $838,901 across 1,039 general payments and $11,012 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $66,594 84
2024 General $94,321 146
2023 General $134,295 192
2022 General $177,211 254
2022 Research $1,250 1
2021 General $146,786 140
2021 Research $3,500 7
2020 General $119,888 91
2020 Research $2,450 4
2019 General $99,806 132
2019 Research $3,812 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eugene Wright
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Eugene Wright were reported at $66,594. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Eugene Wright Internal Medicine median Middle half National median
2019 $99,806 $159 $48–$570 $163
2020 $119,888 $119 $33–$402 $114
2021 $146,786 $135 $37–$521 $132
2022 $177,211 $141 $42–$496 $149
2023 $134,295 $149 $45–$519 $160
2024 $94,321 $154 $47–$537 $164
2025 $66,594 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $265,988 338 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $183,001 242 payments
  3. Lilly USA, LLC $116,143 176 payments
  4. Sanofi-Aventis U.S. LLC $87,474 42 payments
  5. Eli Lilly and Company $65,030 82 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $32,636 70 payments
  7. Embecta Corp. $15,563 4 payments
  8. Novo Nordisk Inc $14,077 21 payments
  9. Boehringer Ingelheim International GmbH $11,383 7 payments
  10. GlaxoSmithKline, LLC. $10,769 12 payments
  11. Other $36,839 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $477,649 191 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $251,330 143 payments
  3. Travel and Lodging $68,216 276 payments
  4. Food and Beverage $23,339 411 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $9,300 5 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,250 2 payments
  7. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $3,500 2 payments
  8. Education $258 8 payments
  9. Gift $59 1 payment
Products named General payments · program years 2019–2025
  1. Kerendia $157,082 210 payments
  2. FreeStyle Libre Pro Diabetes Care $72,463 60 payments
  3. JARDIANCE Diabetes $70,926 70 payments
  4. FreeStyle Libre 3 $49,082 87 payments
  5. FreeStyle Libre Diabetes Care $41,119 37 payments
  6. MOUNJARO $39,874 70 payments
  7. FreeStyle Libre Diabetes Care $36,995 60 payments
  8. FreeStyle Libre Pro Diabetes Care $35,363 29 payments
  9. TOUJEO $32,793 11 payments
  10. JARDIANCE Diabetes $28,244 47 payments
  11. Other $97,234 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $11,012 16 payments

Records

1,055 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record